| The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion N Fenouille, M Tichet, M Dufies, A Pottier, A Mogha, JK Soo, S Rocchi, ... PloS one 7 (7), e40378, 2012 | 243 | 2012 |
| Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner M Cerezo, M Tichet, P Abbe, M Ohanna, A Lehraiki, F Rouaud, M Allegra, ... Molecular cancer therapeutics 12 (8), 1605-1615, 2013 | 232 | 2013 |
| Tumour-derived SPARC drives vascular permeability and extravasation through endothelial VCAM1 signalling to promote metastasis M Tichet, V Prod’Homme, N Fenouille, D Ambrosetti, A Mallavialle, ... Nature communications 6 (1), 6993, 2015 | 185 | 2015 |
| PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells L Codarri Deak, V Nicolini, M Hashimoto, M Karagianni, PC Schwalie, ... Nature 610 (7930), 161-172, 2022 | 101 | 2022 |
| Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway M Rathore, C Girard, M Ohanna, M Tichet, R Ben Jouira, E Garcia, ... Oncogene 38 (30), 5873-5889, 2019 | 88 | 2019 |
| SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival N Fenouille, A Puissant, M Tichet, G Zimniak, P Abbe, A Mallavialle, ... Oncogene 30 (49), 4887-4900, 2011 | 88 | 2011 |
| SIGMAR1 regulates membrane electrical activity in response to extracellular matrix stimulation to drive cancer cell invasiveness D Crottes, R Rapetti-Mauss, F Alcaraz-Perez, M Tichet, G Gariano, ... Cancer research 76 (3), 607-618, 2016 | 60 | 2016 |
| Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction A Brémond, O Meynet, K Mahiddine, S Coito, M Tichet, K Scotlandi, ... Blood, The Journal of the American Society of Hematology 113 (2), 347-357, 2009 | 54 | 2009 |
| The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression N Fenouille, G Robert, M Tichet, A Puissant, M Dufies, S Rocchi, ... Pigment cell & melanoma research 24 (1), 219-232, 2011 | 53 | 2011 |
| Targeting the proteasome-associated deubiquitinating enzyme USP14 impairs melanoma cell survival and overcomes resistance to MAPK-targeting therapies R Didier, A Mallavialle, R Ben Jouira, MA Domdom, M Tichet, P Auberger, ... Molecular cancer therapeutics 17 (7), 1416-1429, 2018 | 52 | 2018 |
| Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness A Puissant, M Dufies, N Fenouille, I Ben Sahra, A Jacquel, G Robert, ... Journal of molecular cell biology 4 (4), 207-220, 2012 | 51 | 2012 |
| Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages M Tichet, S Wullschleger, A Chryplewicz, N Fournier, R Marcone, ... Immunity 56 (1), 162-179. e6, 2023 | 38 | 2023 |
| Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity A Chryplewicz, J Scotton, M Tichet, A Zomer, K Shchors, JA Joyce, ... Cancer Cell 40 (10), 1111-1127. e9, 2022 | 38 | 2022 |
| ALK7 signaling manifests a homeostatic tissue barrier that is abrogated during tumorigenesis and metastasis IP Michael, S Saghafinia, M Tichet, N Zangger, I Marinoni, A Perren, ... Developmental cell 49 (3), 409-424. e6, 2019 | 36 | 2019 |
| Nanoparticle conjugation of human papillomavirus 16 E7-long peptides enhances therapeutic vaccine efficacy against solid tumors in mice G Galliverti, M Tichet, S Domingos-Pereira, S Hauert, D Nardelli-Haefliger, ... Cancer immunology research 6 (11), 1301-1313, 2018 | 30 | 2018 |
| Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers G Galliverti, S Wullschleger, M Tichet, D Murugan, N Zangger, W Horton, ... Cancer immunology research 8 (1), 131-145, 2020 | 28 | 2020 |
| Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion Q Zeng, S Saghafinia, A Chryplewicz, N Fournier, L Christe, YQ Xie, ... Science 378 (6621), eabl7207, 2022 | 20 | 2022 |
| Risk for nevus transformation and melanoma proliferation and invasion during natalizumab treatment: four years of dermoscopic follow-up with immunohistological studies and … M Pharaon, M Tichet, C Lebrun-Frénay, S Tartare-Deckert, T Passeron JAMA dermatology 150 (8), 901-903, 2014 | 14 | 2014 |
| CMSO EA Allen, A Baflast, SB Nejad, E Brindle, N Rae, L Cai, K Cheng, ... | 2 | 2002 |
| Methods and compositions for treating melanoma M Deckert, S TARTARE-DECKERT, M Rathore, M Tichet US Patent App. 17/607,552, 2022 | 1 | 2022 |
Sophie Tartare-DeckertResearch Director INSERMAdresse e-mail validée de unice.fr
